Shorter radiation course may spare breast cancer patients side effects
NCT ID NCT01266642
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a shorter course of higher-dose radiation (hypofractionated) is as good as or better than standard radiation for early-stage breast cancer. About 300 women with ductal carcinoma in situ or early invasive breast cancer are participating. The main goal is to see if the shorter schedule leads to fewer cosmetic side effects while still controlling the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- radiation therapy
- What this could lead to
- If successful, this could offer a more convenient and less side-effect-prone radiation schedule for early breast cancer patients.
- What could go wrong
- This is a phase 2 trial with 301 participants, so results are preliminary. The shorter schedule may not be as effective or could have unforeseen long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCTAL BREAST CARCINOMA IN SITU are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson League City
League City, Texas, 77573, United States
-
MD Anderson West Houston
Houston, Texas, 77079, United States
-
MD Anderson in Sugar Land
Sugar Land, Texas, 77478, United States
-
MD Anderson in The Woodlands
Conroe, Texas, 77384, United States
-
UF Cancer Center at Orlando Health
Orlando, Florida, 32806, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Fasting during chemo: a new way to boost treatment?
- Could a common cholesterol drug boost breast cancer treatment?
- Gene test could guide breast cancer treatment to boost survival
- Vaccine aims to block return of aggressive breast cancer
- One-Week radiation for breast cancer: MRI precision may cut side effects